AI-based system for early detection of skin cancer
Clinical Validation Study of a CAD System With Artificial Intelligence Algorithms for Early Non-invasive Detection of in Vivo Cutaneous Melanoma
This study is testing an AI system that helps doctors spot skin cancer early by comparing its accuracy to that of trained dermatologists using images of suspicious skin lesions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AI Labs Group S.L Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Barakaldo, Biscay) |
| Trial ID | NCT06221397 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate an AI-powered computer-aided diagnosis (CAD) system for the early detection of cutaneous melanoma using images captured by a dermatoscopic camera. It will assess the reliability of the AI algorithm in identifying melanoma compared to evaluations made by dermatologists and primary care physicians. The study will take place at the Dermatology Departments of Cruces University Hospital and Basurto University Hospital, focusing on patients with skin lesions suspected of malignancy. The research seeks to improve early diagnosis and patient outcomes through advanced technology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with skin lesions that are suspected to be malignant.
Not a fit: Patients under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance early detection of melanoma, leading to better treatment outcomes and increased survival rates for patients.
How similar studies have performed: Other studies have shown promising results with AI-based diagnostic tools for melanoma detection, indicating a growing body of evidence supporting this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with skin lesions with suspected malignancy * Age over 18 years old * Patients who consent to participate in the study by signing the Informed Consent form Exclusion Criteria: * Patients under 18 years of age
Where this trial is running
Barakaldo, Biscay
- University Hospital of Cruces — Barakaldo, Biscay, Spain (Recruiting)
Study contacts
- Principal investigator: Jesús Gardeazabal, PhD — Hospital de Cruces
- Study coordinator: Alfonso Medela, MsC
- Email: alfonso@legit.health
- Phone: +34 638127476
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.